LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "idh2 mutant" as a keyword



IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.

Sign Up to like & get
recommendations! Published in 2018 at "Neuro-oncology"

DOI: 10.1093/neuonc/noy014

Abstract: 716 IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas Diffuse gliomas are classified according to the 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System, 1 which… read more here.

Keywords: gliomas; idh2 mutant; 19q codeletion; idh2 ... See more keywords

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)

Sign Up to like & get
recommendations! Published in 2025 at "Blood"

DOI: 10.1182/blood-2025-3466

Abstract: Acute myeloid leukemia (AML) with an IDH2 mutation represents a distinct molecular subtype with sensitivity to venetoclax-based regimens. In the VIALE A trial, 56% of IDH2 mutant patients treated with azacitidine and venetoclax achieved a… read more here.

Keywords: astx727 venetoclax; trial; idh2 mutant; mutant aml ... See more keywords

A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2025.43.16_suppl.3087

Abstract: 3087 Background: Pre-clinical data have shown that mutations in isocitrate dehydrogenase (IDH) 1 and 2 can lead to a “BRCAness” phenotype by impairing homologous recombination (HR) repair. Olaparib, a PARP inhibitor effective in BRCA-mutated cancers… read more here.

Keywords: idh1 idh2; mutant; solid tumors; idh2 mutant ... See more keywords
Photo from wikipedia

All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells

Sign Up to like & get
recommendations! Published in 2020 at "Yonsei Medical Journal"

DOI: 10.3349/ymj.2020.61.9.762

Abstract: Purpose Pharmacological inhibition of mutant isocitrate dehydrogenase (IDH) reduces R-2-hydroxyglutarate (2-HG) levels and restores cellular differentiation in vivo and in vitro. The IDH2 inhibitor enasidenib (AG-221) has been approved by the FDA as a first-in-class… read more here.

Keywords: 221 atra; differentiation; aml cells; idh2 mutant ... See more keywords